REG - Allergy Therapeutics Abbott Laboratories - Holding(s) in Company <Origin Href="QuoteRef">ABT.N</Origin> <Origin Href="QuoteRef">AGY.L</Origin>

Abbott LaboratoriesAnnouncement

27/11/2015 15:31

RNS Number : 2532H
Allergy Therapeutics PLC
27 November 2015
For filings with the FCA include the annex

For filings with issuer exclude the annex


TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi


1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:ii
Allergy Therapeutics plc 
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights
X
Other (please specify):


3. Full name of person(s) subject to the
notification obligation:iii
Abbott Laboratories 
4. Full name of shareholder(s)
(if different from 3.):iv
CFR lnternational SpA
Yissum Holding Limited
5. Date of the transaction and date on
which the threshold is crossed or
reached:v
20 November 2015 
6. Date on which issuer notified:
20 November 2015
7. Threshold(s) that is/are crossed or
reached: vi, vii
Below 41%
8. Notified details:
A: Voting rights attached to sharesviii, ix
Class/type of
shares

if possible using
the ISIN CODE
Situation previous
to the triggering
transaction
Resulting situation after the triggering transaction
Number
of
Shares
Number
of
Voting
Rights
Number
of shares
Number of voting
rights
% of voting rights x
Direct
Direct xi
Indirect xii
Direct
Indirect
Ord GBP 0.01
240,584,571
240,584,571


240,584,571

40.995%
GB00B02LCQ05

B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial
instrument
Expiration
date xiii
Exercise/
Conversion Period xiv
Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.
% of voting
rights






C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial
instrument
Exercise price
Expiration date xvii
Exercise/
Conversion period xviii
Number of voting rights instrument refers to
% of voting rights xix, xx




Nominal
Delta



Total (A+B+C)
Number of voting rights
Percentage of voting rights
240,584,571
40.995%
9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: xxi
Through a series of controlled undertakings, Abbott Laboratories has an indirect holding of 99.9% of the shares in CFR Pharmaceuticals, SA. 
CFR Pharmaceuticals SA's wholly owned subsidiary, CFR International SPA, holds 17.567% of the voting rights in Allergy Therapeutics plc directly and 23.428% of the voting rights in Allergy Therapeutics plc indirectly. CFR International SPA also has a 100% interest in Yissum Holding Limited, which directly holds 23.428% of shares in Allergy Therapeutics plc.

Proxy Voting:
10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease
to hold:

12. Date on which proxy holder will cease to hold
voting rights:



13. Additional information:


14. Contact name:
Des Peters
15. Contact telephone number:
+1 224-667-6545

This information is provided by RNS
The company news service from the London Stock Exchange
  END
HOLUBAVRVBAAUAA